GSK GB00BN7SWP63

Report

Delayed London Stock Exchange - 11:35 2022-11-25 am EST
1392.40	GBX		+0.90%

11/25	GSK Canada Submits Respiratory Syncytial Virus Vaccine Candidate For Regulatory Review	RE
11/25	Gsk canada submits respiratory syncytial virus (rsv) vaccine can…	RE
11/25	FTSE 100 flat as housing, retail stocks weigh	RE

All news about GSK PLC

11/25	GSK Canada Submits Respiratory Syncytial Virus Vaccine Candidate For Regulatory Review	RE
11/25	Gsk canada submits respiratory syncytial virus (rsv) vaccine can…	RE
11/25	FTSE 100 flat as housing, retail stocks weigh	RE
11/24	Researchers test mRNA technology for universal flu vaccine	RE
11/24	Analyst recommendations: Apple, Dollar Tree, GSK...
11/24	GSK : Berenberg reiterates its Buy rating	MD
11/23	GSK provides an update on Blenrep US marketing authorisation	AQ
11/23	GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisatio..	AQ
11/22	MarketScreener’s World Press Review : November 22, 2..
11/22	GSK to Withdraw US Marketing Authorization for Cancer Drug After FDA Request	MT
11/22	GSK to Pull Out Multiple Myeloma Drug from US Market Following Disappointing Late-stage..	MT
11/22	CORRECT: LONDON MARKET OPEN: Oil stocks lift FTSE amid China concerns	AN
11/22	LONDON MARKET OPEN: Oil stocks lift FTSE 100; China concerns persist	AN
11/22	FTSE 100 hits two-month high as oil stocks rebound	RE
11/22	TOP NEWS: GSK suffers setback as FDA demands withdrawal of cancer drug	AN
11/22	LONDON BRIEFING: FTSE 100 called higher as oil prices firm overnight	AN
11/22	GSK To Withdraw Blenrep's US Marketing Authorization After FDA Request	DJ
11/22	GSK Seeks Cancelation Of US FDA Nod For Blood Cancer Drug After Phase 3 Study Failure	MT
11/22	GSK to stop selling blood cancer drug Blenrep in United States	RE
11/22	GSK Withdraws U.S. Marketing Authorisation For Blood Cancer Drug Blenrep	RE
11/22	GSK to withdraw blood cancer drug from U.S. after trial failure	RE
11/21	Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday..	MT
11/21	FTSE 100 eases as China COVID surge knocks energy, mining stocks	RE
11/18	Vaccines and drugs in the pipeline for RSV	RE
11/17	U.S. FDA greenlights Provention Bio's diabetes drug	RE
11/17	U.S. FDA greenlights Provention Bio's diabetes drug	RE
11/17	Britain's Mitie offers workers winter support package	RE
11/17	GSK PLC : Ex-dividend day for interim dividend	FA
11/16	CureVac to Deliver Phase 1 Results for Influenza, COVID-19 in Q1 2023	MT
11/16	European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh	MT
11/16	UK dividends calendar - next 7 days	AN
11/15	UK Drug Pricing Agency Rejects Merck & Co.'s Molnupiravir, Four Other COVID-19 Treatmen..	MT
11/15	Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective	RE
11/15	European Markets Move Higher Helped by Upbeat US Inflation Data	MT
11/15	UK dividends calendar - next 7 days	AN
11/15	Gsk : tops Access to Medicine Index (ATMI) for eighth consecutive time	PU
11/15	Big pharma not doing enough to improve drug access - analysis	RE
11/15	Gsk : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	PU
11/15	LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperfor..	AN
11/15	GSK Expects to Accept $2 Billion from Tender Offer for Guaranteed Notes	MT
11/14	GSK plc Announces Positive Phase IIa Study Results for A New First-In-Class Candidate M..	CI
11/14	European ADRs Continue to Trend Higher in Monday Trading	MT
11/14	UK dividends calendar - next 7 days	AN
11/14	GSK Says Investigational Agent Was Well Tolerated Among Pulmonary Tuberculosis Patients..	MT
11/14	Gsk : announces positive Phase IIa study results for a new first-in-class candidate medici..	PU
11/14	GSK Announces Positive Phase IIa Study Results For New First-In-Class Candidate Medicin..	RE
11/14	Gsk: gsk3036656 showed early bactericidal activity with low, onc…	RE
11/14	Gsk - treatment was generally well tolerated with no serious adv…	RE
11/14	Gsk: announces positive phase iia study results for a new first-…	RE
11/14	GSK provides an update on Zejula (niraparib) US prescribing information	AQ
11/11	Health Care Down Sharply on Rotation -- Health Care Roundup	DJ
11/11	Most European Bourses Finish in the Green, But UK FTSE 100 Falls Amid Recession Worries	MT
11/11	Correction: US FDA Restricts Second-line Use Of GSK's Zejula In Ovarian Cance..	MT
11/11	European ADRs Move Slightly Lower in Friday Trading	MT
11/11	UK dividends calendar - next 7 days	AN
11/11	GSK to Limit Ovarian Cancer Treatment Zejula's Second-Line Maintenance Indication in US	MT
11/11	There's a party in the USA
11/11	GSK : Downgraded to Sell by UBS	MD
11/11	GSK to restrict US use of cancer drug Zejula to some populations	AN
11/11	UBS Downgrades GSK to Sell from Neutral, Cuts PT	MT
11/11	Analyst recommendations: Intel, Roku, GSK...
11/11	LONDON BROKER RATINGS: UBS cuts Smurfit and GSK; Jefferies likes M..	AN
11/11	GSK Will Limit Use of Zejula in the US	DJ
11/11	US FDA Restricts Second-line Use Of GSK's Zejula In Ovarian Cancer With BRCA Mutations	MT
11/11	GSK to limit U.S. use of ovarian cancer drug to some populations	RE
11/11	GSK plc Provides Update on Zejula 2L in US	CI
11/10	European Commission Approves Sanofi and GSK's Next-Generation Covid-19 Booster Vaccine ..	CI
11/10	GSK Says Sanofi-GSK COVID Booster Vaccine Approved By EU	RE
11/10	LONDON MARKET CLOSE: Cooling US inflation triggers risk-on rally	AN
11/10	Sanofi, GSK's COVID-19 Booster Shot Gets Regulatory Nod in Europe	MT
11/10	UK dividends calendar - next 7 days	AN
11/10	Sanofi-GSK COVID-19 Jab Gets EU Commission Approval as Booster	MT
11/10	TOP NEWS: Haleon upgrades yearly revenue growth forecast	AN
11/10	LONDON MARKET OPEN: Centrica helps FTSE 100 outperform ahead of US CP..	AN
11/10	Haleon Upgrades 2022 Views After 3Q Revenue Rose on Pricing, Volumes	DJ

1 2 3 4 5 6 7 8 9 10 Next

Analysis

Big pharma not doing enough to improve drug access - analysis